Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0M0UU
|
||||
Former ID |
DIB001415
|
||||
Drug Name |
ZYGK-1
|
||||
Synonyms |
Glucokinase activator (oral, diabetes), Zydus-Cadila
|
||||
Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Phase 1 | [523690] | ||
Company |
Zydus-Cadila Group
|
||||
Target and Pathway | |||||
Target(s) | Glucokinase | Target Info | Activator | [543714] | |
KEGG Pathway | Glycolysis / Gluconeogenesis | ||||
Galactose metabolism | |||||
Starch and sucrose metabolism | |||||
Amino sugar and nucleotide sugar metabolism | |||||
Butirosin and neomycin biosynthesis | |||||
Metabolic pathways | |||||
Biosynthesis of antibiotics | |||||
Carbon metabolism | |||||
Insulin signaling pathway | |||||
Insulin secretion | |||||
Prolactin signaling pathway | |||||
Glucagon signaling pathway | |||||
Type II diabetes mellitus | |||||
Maturity onset diabetes of the young | |||||
Central carbon metabolism in cancer | |||||
Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
HIF-1-alpha transcription factor network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.